Quantum-Si to Participate in B. Riley Securities’ Life Sciences Tools Conference – Proteomics Setting the Blueprint for Innovative Drug Creation, Virtual Conference

GUILFORD, Conn.–(BUSINESS WIRE)–Mar. 24, 2023–
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company^TM, today announced that it will be participating in B. Riley Securities’ Life Sciences Tools Conference – Proteomics Setting the Blueprint for Innovative Drug Creation, Virtual Conference to be held on Thursday, April 6, 2023.

Patrick Schneider, Ph.D., Quantum-Si’s President and Chief Operating Officer, will participate in the panel discussion “How to Translate Insights from Proteomics and Advances in AI into Drug Discovery and Innovation?” at 10:30 AM ET.

Additionally, Jeff Hawkins, Quantum-Si’s Chief Executive Officer, and Dr. Schneider will participate in a fireside chat at 2:30 PM ET.

A link for live and archived webcasts of both events will be available in the “Investors” section of the Quantum-Si website under Events & Presentations.

About Quantum-Si Incorporated

Quantum-Si, The Protein Sequencing Company^TM, is focused on revolutionizing the growing field of proteomics. The Company’s suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at www.quantum-si.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230324005113/en/

Investor

Juan Avendano

[email protected]

Media

Michael Sullivan

[email protected]

Source: Quantum-Si Incorporated